LICENCING & COMPLIANCE
Celadon is one of the first UK companies to be awarded licences by UK regulators and MHRA to cultivate and manufacture high-THC medicinal cannabis. The company operates in a highly regulated environment and as such is committed to the following standards and licences:
This is the licence required for Celadon to cultivate, store and manufacture pharmaceutical cannabis at its facility.
This is the certification required to cultivate cannabis flowers for wholesale distribution or for use in pharmaceutical manufacturing.
Celadon’s indoor, hydroponic cultivation technology enables pharmaceutical level consistency and repeatability, to the tightest tolerance, in order to produce a pharmaceutical-grade GMP product; this is much harder to achieve using conventional greenhouse cultivation approaches.
This is the gold-standard pharmaceutical certification granted by the Medicines and Healthcare Products Regulatory Agency (MHRA) required to manufacture medicines for human consumption.
Celadon is one of a small number of companies globally of its kind to be awarded GMP certification for a natural high-THC API.
This milestone licence will enable Celadon to sell its high-THC API into the manufacturing market for the development of pharmaceutical medicines, subject to an update to its existing licence by UK regulators, as well as enable Celadon to use its API in the development of its own finished medicines for both clinical trials and selling under the “specials” framework in the UK. It also enables Celadon to partner with world-leading pharmaceutical companies who wish to manufacture cannabinoid-based medicines, whether THC, CBD or other cannabinoids.
Celadon’s proprietary API manufacturing process is led by its in-house Production and Quality teams to ensure the highest quality pharmaceutical product.